Cali Pharmaceuticals LLC

Quick facts

Phase 3 pipeline

• CPL-01 · Diabetes
  CPL-01 is a small molecule that targets the SGLT2 receptor.
• Local anesthetic injection of CPL-01 · Pain Management / Anesthesia
  CPL-01 is a local anesthetic injection that blocks nerve conduction to provide localized pain relief and anesthesia at the injection site.
• Naropin, 0.5% Injectable Solution · Pain management
  Naropin is a local anesthetic that works by blocking sodium channels in nerve fibers, preventing the initiation and transmission of nerve impulses.

Phase 2 pipeline

• Analgesic Non Narcotic · Oncology
  Blocks NMDA receptors to reduce pain perception

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Cali Pharmaceuticals LLC portfolio CI brief
• Cali Pharmaceuticals LLC pipeline updates RSS